Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series.

@article{Saperstein2002PhotodynamicTO,
  title={Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series.},
  author={David A. Saperstein and Philip J. Rosenfeld and Neil M. Bressler and Robert H. Rosa and Michel Sickenberg and Paul Sternberg and Thomas M. Aaberg and Troy Albert Reaves},
  journal={Ophthalmology},
  year={2002},
  volume={109 8},
  pages={1499-505}
}
OBJECTIVE To evaluate the safety and effect on visual acuity of photodynamic therapy with verteporfin (Visudyne, Novartis AG) in patients with subfoveal choroidal neovascularization (CNV) secondary to the ocular histoplasmosis syndrome (OHS). DESIGN Open-label, three-center, noncomparative prospective case series. PARTICIPANTS OHS patients with subfoveal CNV lesions no larger than 5400 micro m in greatest linear dimension (GLD) with classic or occult CNV extending under the geometric center… CONTINUE READING